Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Adult NF1
NCT00754780Phase 2
Key facts
- Status
- Completed
- Start
- Sep 2000
- Primary completion
- Aug 2004
- Sponsor
- Mayo Clinic
- Modality
- Small Molecules
- Drugs
- pirfenidone
- Conditions
- neurofibromatosis type 1 (NF1)
01
Overview
Phase 2, open-label, single-arm trial of pirfenidone in neurofibromatosis type 1 (NF1), sponsored by Mayo Clinic. Primary endpoint: Tumor Volume at 24 months. Started Sep 2000; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Pirfenidone
Oral Pirfenidone 800 mg TID
03
Endpoints
Primary
Tumor Volume
Secondary
Acute, Subacute and Chronic Toxicity
Beyond the preview
Go deeper on NCT00754780.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00754780.